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Thanks to major advances in the field of surgical techniques and neoadjuvant chemoradiation therapy, along with more
accurate pre-operative staging tools and the widespread introduction of population-based screening programs, treatment
of rectal cancer has been evolving over the past few decades, moving towards a more tailored approach. This has brought a
shift in the treatment algorithm of benign rectal lesions and selected early rectal cancers, for which today transanal
endoscopic microsurgery (TEM) is accepted as an effective alternative to abdominal surgery.
In 2013, topics of controversy are the role of TEM in the treatment of more advanced rectal cancers, in cases of complete
pathological response after chemoradiation therapy and the role of TEM as a platform for single-port surgery and NOTES.
This article reviews the current indications for TEM and the future perspectives of this approach in the treatment of rectal
tumors.
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INTRODUCTION
Transanal endoscopic microsurgery (TEM) is a minimally
invasive technique that was conceived almost 30 years
ago as an alternative to abdominal rectal resection and
conventional transanal techniques, for the removal of
large polyps localized in the rectum and not amenable to
endoscopic resection [1]. While transanal local excision with
retractors is associated with a significant incidence of local
recurrence—in particular for tumors located in the proxi-
mal rectum [2, 3], TEM provides a transanal approach with
low recurrence rates, thanks to an extremely precise dissec-
tion due to enhanced and stable visualization of the surgi-
cal field. In addition, the full-thickness en bloc excision
allows accurate pathological evaluation of the specimen
with precise staging of the disease.
Today, abdominal rectal resection, combined with total
mesorectal excision (TME), is the ‘gold standard’ in the
surgical treatment of rectal cancer. However, the postoper-
ative course is burdened by significant mortality and mor-
bidity [4–7]. Compared with abdominal surgery, TEM offers
the advantage of combining a minimally invasive approach
with evident benefits in terms of postoperative morbidity
and recovery and long-term functional outcomes and qual-
ity of life [8]. While TEM has revolutionised technique and
outcome of transanal surgery, becoming the ‘gold stan-
dard’ for the treatment of large rectal adenomas [9–12],
concerns remain about its role in the treatment of rectal
cancer, mainly due to the lack of adequate lymphadenect-
omy. This manuscript aims to review current indications and
future perspectives of TEM.
SURGICAL TECHNIQUE
In many centers, a TEM procedure is now performed with
TEO (transanal endoscopic operation) instrumentation by
Karl Storz GmbH (Tuttlingen, Germany). The equipment
includes a 7 or 15 cm rectal tube which has a 4 cm diameter
and three working channels (12, 5 and 5mm) for dedicated
or conventional laparoscopic instruments and a 5mm chan-
nel for a 308 2D scope. The proctoscope is connected to the
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operating table via a holding arm consisting of three joints
and a single screw. The system is used in combination with
standard laparoscopic units. Camera imaging is projected
on screen and insufflation is obtained by a conventional
CO2 thermo-insufflator. The shape of the tip of the procto-
scope allows manipulation and suturing of the rectal wall
on a 3608 surface.
Recently, transanal minimally invasive surgery (TAMIS),
using equipment for single-incision laparoscopic surgery
(SILS), has been proposed as an alternative to TEM.
Indications and surgical technique are the same as for
TEM [13]. There is a lower cost for the disposable SILS
equipment, compared with the reusable TEM device.
However, no comparative studies aimed at evaluating the
benefits in terms of costs and clinical outcome of TAMIS
versus TEM in high volume centers over long periods of
time have been published.
The TEM procedure is usually performed under general
anesthesia. The patient is placed either prone or supine in
order to keep the lesion as close to the 6 o’clock position as
possible. Patients with lateral lesions are usually placed in
the supine position unless the lesion is predominantly
located in the right or left upper quadrant (i.e. 12 to 3-,
or 9 to 12 o’clock position). With circumferential lesions,
the patient is always positioned prone due to the higher
risk of entering the peritoneal cavity and the consequent
need to reduce the descent of small bowel loops into the
surgical field while repairing the opening itself.
After insertion of the proctoscope, the lesion is identified
and the proctoscope is fixed. Its position is adjusted
throughout the procedure in order to ensure optimal visu-
alization and access to the margins of the lesion. High-flow
CO2 insufflation is required and endoluminal pressure is
generally maintained at 8mmHg, although it might need
to be increased to 16mmHg.
Dissection usually begins at the right lower border of
the tumor. A macroscopic margin of at least 5mm from
the neoplasm needs to be obtained with both benign and
malignant lesions. Tumor excision is performed by monopo-
lar hook cautery. In difficult cases, ultrasonic shears or
an electrothermal bipolar vessel sealing systemmay be help-
ful. Dissection is continued circumferentially around the
lesion to the perirectal fat. Due to the uncertainty of the
pre-operative diagnosis and staging, full-thickness resection
with adequate margins of clearance should be performed.
The specimen is retrieved transanally and is pinnedona cork-
board before fixation in 10% buffered formalin, in order
to preserve the margins of normal mucosa surrounding the
tumor. The specimen is analysed by permanent section.
After disinfection of the parietal defect with iodopovi-
done solution, the rectal wall is always closed with one or
more Maxon 3-0 (Codisan S.p.A.) running sutures secured
with dedicated silver clips (Richard Wolf, Knittingen,
Germany). These clips serve to anchor the suture in place,
since knot tying during TEM is challenging. As an alterna-
tive, the Endo StitchTM single-use suturing device can also
be used. At this stage, the endoluminal pressure may be
reduced to allow better compliance of the rectal wall.
Suturing is performed with particular attention to the
integrity of the rectal lumen. Therefore, when suturing
large defects, a midline stitch is placed to approximate
proximal and distal margins. At the end of the procedure,
patency of the rectum is carefully verified through the TEM
proctoscope.
CURRENT INDICATIONS
TEM for rectal adenomas
Endoscopic resection represents the treatment of choice
for pre-malignant lesions of the gastrointestinal tract.
However, conventional endoscopic mucosal resection
(EMR) cannot provide an en-bloc resection in case of large
lesions and incomplete or piecemeal resection may occur in
up to 50% of cases [14]. After piecemeal resection, patho-
logical assessment of complete resection is challenging and
the risk of local recurrence is high [15]. In addition, EMR
does not provide a submucosal dissection, therefore pre-
cluding an accurate staging in case of malignancy.
In the last few years, the endoscopic submucosal dissec-
tion (ESD) technique was introduced to overcome these dif-
ficulties and to allow en bloc resection of specimens,
especially in case of lesions larger than 20mm [16]. Low
complication rates and low local recurrence rates have
been reported after ESD [17–19]; however, compared
with conventional EMR, ESD is technically more challenging
and time consuming, requiring a steep learning curve [17,
20]. As a result, ESD has not gained wide acceptance in west-
ern countries and transanal surgery is still the approach of
choice for the excision of large rectal adenomas.
Today, no studies have compared endoscopic techniques
with transanal surgery for large rectal adenomas. Barendse
et al. [21] published a systematic review on safety and ef-
fectiveness of EMR versus TEM for large rectal adenomas,
including 20 prospective and non-prospective case series
employing EMR technique and 48 employing TEM tech-
nique with similar follow-up periods. Postoperative compli-
cation rates were 3.8% for EMR vs 13.0% for TEM
(P< 0.001). Local recurrence rates were assessed in 3890 pa-
tients (1030 EMR and 2860 TEM). Early local recurrence
after single intervention in the EMR series was significantly
higher than in the TEM series (11.2 vs 5.4%, respectively;
P= 0.04), while late recurrence rates were similar in both
groups of patients: 1.5% for EMR vs 3.0% for TEM
(P=0.29). The authors concluded that EMR for large
rectal adenomas appears to be less effective but safer
than TEM.
However, because of the low quality of the studies
included in this analysis, no definitive conclusions can be
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drawn and the results of prospective randomized trials are
needed to assess the role of TEM compared with EMR/ESD
in the treatment of rectal adenomas.
Several transanal techniques for excision of rectal polyps
unsuitable for endoscopic resection have been described,
including conventional transanal resection (TE) with retrac-
tors and TEM [22]. Local recurrence rates range from 4–57%
after TE and from 2.4–16% after TEM [23].
Several studies have compared conventional TE to TEM
for adenoma, reporting significantly better long-term
results after TEM. For instance, Langer et al. retrospectively
compared the long-term outcomes of 54 patients undergo-
ing conventional TE and 57 patients undergoing a TEM
procedure for rectal adenoma [24]. They reported a signif-
icantly higher local recurrence rate after TE than after TEM
(31.5 vs 8.8%, respectively). Similar results were published
by Moore et al., who reviewed the outcomes of 40 patients
undergoing TEM and 38 undergoing TE [25]. They reported
a significantly higher rate of negative margins (83 vs 61%;
P= 0.03), a trend toward a reduced rate of specimen frag-
mentation (12% vs 26%; P= 0.12) and a significantly
lower local recurrence rate (3 vs 32%; P=0.003) after
TEM, compared with TE. Finally, the findings reported by
de Graaf et al. support the superiority of TEM over classical
TE with regard to surgical margins status, specimen
fragmentation and local recurrence [26]. They observed
negative resection margins in 88% of specimens after
TEM compared with 50% after TE (P< 0.001), fragmenta-
tion of the specimen in 1.4% of case after TEM and 23.8%
after TE (P< 0.001) and local recurrence rate of 6.1% after
TEM, compared with 28.7% after TE (P< 0.001).
Therefore, based on the data reported in the literature,
TEM represents the current standard of treatment for
large rectal adenomas and conventional TE should be
abandoned.
Residual adenomatous tissue is detected in the surgical
margins in 0–37% of TEM procedures and positive surgical
margins are independent risk factors for local recurrence
[12, 27]. Despite such high positive-residual-margin rates,
reported recurrence rates are significantly lower, ranging
from 3–16% [23]. This could be explained by the fact that
diathermic damage to the remaining adenomatous tissue
during the dissection may cause the sterilization of the
margins.
Another risk factor for local recurrence is the size of the
adenoma. In our clinical practice, a full-thickness incision of
the rectal wall is always initiated at a distance of approxi-
mately 5mm around the tumor. Nevertheless, in our series
of 293 large rectal adenomas treated by TEM [12], 21% of
adenomas with a diameter 5 cm were removed with pos-
itive margins, versus 9% of adenomas <5 cm (P= 0.047).
Tumor diameter 5 cm was found to be a predictive
factor for local recurrence (P= 0.007).
Our results compare favorably with those reported by
McCloud et al. in a series of 75 patients undergoing TEM
for adenoma [28]. They found a significantly higher local
recurrence rate at 12 months for adenomas larger than
10 cm, compared with those with a diameter between
5 and 10 cm and those smaller than 5 cm (33.3 vs 21.7 vs
7.7%, respectively; P= 0.035). Similarly, Scala et al. recently
looked at the outcomes of 279 TEM procedures performed
for benign lesions [29], reporting significantly increased
local recurrence rates for lesions larger than 5 cm.
Since a local recurrence is relatively common after
excision of adenomas larger than 5 cm, a strict clinical and
endoscopic follow-up is highly recommended in these cases.
However, TEM has been shown to be an important thera-
peutic option even in the treatment of recurrent adenoma,
when the endoscopic resection is not feasible. Several series
have reported on the safety and effectiveness of TEM in the
treatment of recurrent adenoma and no increased periop-
erative morbidity and no further cases of local recurrence
have been described [11, 12, 28, 30–33].
Finally, in 2012 there are still some limitations in the
pre-operative diagnosis of large rectal adenomas. Even
though EUS appears to be the most accurate pre-operative
diagnostic tool for investigating tumor invasion of the
rectal wall, discrepancy rates up to 20% between pre-
operative EUS and pathological staging of the tumors are
reported. Some recent studies have investigated the role of
EUS, compared with magnetic resonance imaging (MRI), for
the staging of large rectal adenomas, reporting similar
rates of over-staging (21.7%) between the two staging
tools. However, MRI might be more appropriate in case
of more proximal rectal tumors that cannot be easily
reached by the EUS probe [34]. In addition, up to 26% of
the adenomas resected by TEM are found, at the definitive
pathological examination, to be invasive adenocarcinoma
[35]. With this in mind, an appropriate full-thickness exci-
sion should be offered to all patients with rectal neoplasm,
even in case of benign pre-operative histology, instead of a
partial wall, piecemeal endoscopic resection. This strength-
ens the concept of TEM as a macrobiopsy that is radical in
case of low-risk pT1 cancers, while it represents the first
step in a multidisciplinary strategy for the treatment of
more advanced rectal cancer that includes rectal resection
and TME and chemoradiation therapy.
TEM for T1 rectal cancer
While TEM is considered the primary form of treatment for
large rectal adenomas judged unsuitable for endoscopic
removal, its role in the treatment of early rectal cancer
(T1) is still controversial, mainly because of the absence of
an adequate lymphadenectomy.
To date, rectal resection with TME is the ‘gold standard’
in the treatment of extraperitoneal rectal cancer [36, 37].
However, local recurrence can develop even after a radical
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resection with complete TME for T1 N0 rectal cancer[38].
In addition, abdominal surgery is associated with significant
mortality and morbidity, including anastomotic leaks, uri-
nary and sexual dysfunction and fecal incontinence [4, 7].
With the widespread introduction of population-based
screening programs, the incidence of early rectal cancer has
progressively risen during the last twenty years, leading to
an increasing scrutiny and debate around the potential role
of TEM in the treatment of early rectal cancer.
A recent meta-analysis of the literature analysed the
short-term and oncological outcomes of the single random-
ized clinical trial and four retrospective, comparative,
non-randomized studies published between 1996 and
2009, that have compared TEM to rectal resection with
TME for T1 rectal cancer [39]. Globally, a significantly
lower postoperative complication rate was reported after
TEM, compared with TME (8.2 vs 47.2%; P=0.01), with no
mortality, confirming the safety of TEM, even in the treat-
ment of early rectal cancers.
A significantly higher local recurrence rate was found
after TEM (12 vs 0.5%; P=0.004). However, the wide
range of local recurrence rates from 4–18% observed
after TEM for T1 rectal cancer in these studies can be ex-
plained by several factors: i) heterogeneity of the studies,
which were often underpowered and had extremely vari-
able follow-up periods, ii) different inclusion criteria and iii)
lack of differentiation between ‘low risk’ (well or moder-
ately differentiated adenocarcinoma without lymphatic
invasion) or ‘high-risk’ carcinoma (poorly or undifferen-
tiated adenocarcinoma with lymphatic invasion) in the
majority of them.
The only two comparative studies that have analysed
long-term outcomes of TEM for T1 rectal cancers, classified
according to Hermanek criteria, are those published by
Heintz et al. in 1998 and by Lee et al. in 2003 [40, 41].
Heintz et al. did not observe significant differences in
terms of local recurrence after TEM compared with TME
(4 vs 3%) in case of a T1 low-risk cancer, while a local
recurrence was more frequent after TEM than TME in
case of a ‘high risk’ cancer (33 vs 18%) [40]. Similar results
were obtained by Lee et al. in 52 patients who had under-
gone TME, compared with 17 patients treated by TME for
well- or moderately differentiated rectal carcinomas [41].
They found comparable local recurrence rates (4 vs 0%;
P= 0.95).
Since the early 1990s, several case series have been pub-
lished, assessing oncological outcomes after TEM for T1
rectal cancer [42]. Reported recurrence rates ranged from
0–26%. During the last decade, several risk factors for local
recurrence after TEM for T1 rectal cancer have been evalu-
ated, other than the degree of tumor differentiation and
the lympho-vascular invasion. They include positive resec-
tion margins, the tumor diameter and the T-stage accord-
ing to submucosal invasion [43, 44].
A tumor diameter >4 cm is usually considered a risk
factor for recurrence after local excision, as it is associated
with an increased rate of positive margins. However, tumor
involvement of the resection margins in T1 cancers is occa-
sional (about 2%) even in cases of large tumors, when
a full-thickness excision is performed [44]. TEM with a
full-thickness excision allows reduction of the rate of posi-
tive deep margins, while the circumferential mucosal mar-
gins are easily marked before beginning the excision.
Submucosal (sm) invasion is one of the strongest predic-
tors of lymph node metastasis and local recurrence along
with the lympho-vascular invasion. The incidence of lymph
node metastasis is very low for T1 sm1 (0 to 3%), but in-
creases to 15 and 25% for T1 sm2–3 and T2, respectively.
Several studies have specifically looked at the significance
of submucosal invasion as prognostic factor for recurrence
after TEM for T1 rectal cancer [43, 44]. For instance, Bach
et al. [43] used the oncological outcomes, prospectively col-
lected in a multicenter database of 487 rectal cancer pa-
tients (253 pT1) treated by TEM, to construct a predictive
model of local recurrence after TEM. They found that depth
of submucosal invasion >sm1 was an independent predic-
tor of local recurrence, while the risks of recurrence for
sm2–3 and pT2 lesions were similar.
We recently reviewed our series of 107 patients under-
going TEM for rectal cancer. Among the 48 pT1 cancer pa-
tients, during a mean follow-up of 54 months, the overall
recurrence rate was 10.4%. None of the 26 patients with an
sm1 lesion experienced a local recurrence, while a local re-
currence occurred in 5 out of 22 (22.7%) sm2–3 patients
(P=0.036). Sm1 lesions showed a 100% disease-free rate
at 60 months. By multivariate analysis, sm staging was an
independent predictor for recurrence, along with the
tumor grading [44].
Based on the evidence reported in the literature, it seems
evident that an accurate pre-operative evaluation of the
depth of tumor invasion and lymph node metastasis is cru-
cial for proper patient selection for a TEM procedure. EUS
appears to be the most accurate pre-operative diagnostic
tool for investigating the tumor invasion of the rectal wall
[45]. However, EUS is highly operator-dependent and sev-
eral factors, including previous endoscopic biopsies, endo-
scopic manipulation of the tumor and peritumoral
inflammation, may affect the accuracy of the evaluation
of T1 rectal lesions [46]. Therefore, a discrepancy between
pre-operative EUS and definitive pathological staging of
the tumor is quite common, with a risk of under-staging
that is as high as 25% and a risk of over-staging up to 20%.
Nevertheless, the recent introduction of high-definition
20 Mhz through-the-channel mini-probes may permit
better pre-operative identification of not only the T-
staging, but also the depth of submucosal invasion [47].
High-resolution MRI is less operator-dependent and is
widely used for the pre-operative staging of rectal cancer.
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While EUS better shows an early rectal cancer, differentiat-
ing accurately between T1 and T2 rectal cancer, MRI is more
accurate in the detection of mesorectal invasion and in the
evaluation of the distance to the mesorectal fascia [48, 49].
With this in mind, TEM with full-thickness excision should
be used as macrobiopsy and considered a means for staging
early rectal cancer.
Finally, when the definitive pathological evaluation of
the TEM specimen reveals the presence of negative prog-
nostic factors—such as depth of tumor invasion beyond pT1
sm1, poorly differentiated tumor grading, lympho-vascular
invasion or positive resection margins—abdominal surgery
with TME is recommended in order to reduce the risk of
recurrence. There is increasing evidence suggesting that
TEM used as macrobiopsy does not jeopardize long-term
survival of patients who undergo further abdominal
surgery. For instance, Borschitz et al. have retrospectively
compared the oncological outcome of 17 pT1 ‘high risk’
patients undergoing abdominal rectal surgery after TEM
to 66 pT1 ‘low risk’ patients who were treated by TEM
alone [50]. They reported a local recurrence rate of 6%
in both groups. Five-year cancer-free survival was 93%
in the ‘high risk’ patients, compared with 94% in ‘low
risk’ patients. Recently, Levic et al. have reported similar
local recurrence and distant metastasis rates in a
case-matched study that compared patients undergoing
a TME after a TEM procedure to patients treated with
primary TME for rectal cancer (0 vs 8% and 4 vs 12%,
respectively [51].
FUTURE PERSPECTIVES
Neoadjuvant combined-modality therapy and TEM for
T2 N0 rectal cancer
Modern neoadjuvant chemoradiation therapy has been
shown to induce a significant tumor regression, down-
staging and sterilization of perirectal lymph nodes, with
a pathological complete response that is reported in up
to 30% of patients [52]. A recent systematic review and
meta-analysis of the literature has demonstrated that onco-
logical outcomes following pathological complete response
are significantly better, compared with non-responders, in
terms of local recurrence rate, distant metastasis rate and
both overall and disease-free survival at 5 years [53]. Among
the many factors that are implicated in tumor regression,
the interval between completion of neoadjuvant treatment
and surgery seems to play a key role. In particular, patho-
logical complete response appears to be a time-dependent
process [53].
TME is associated with mortality and significant postop-
erative short- and long-term morbidity, including sexual
and urinary dysfunction and stoma-related complications
[4–7, 54, 55]. Since 30% of patients may have a pathological
complete response and they will be subjected to an
‘unnecessary’ procedure associated with significant
short-term and long-term morbidity, there is an increasing
interest in properly identifying these patients in order to be
able to offer a less invasive—and still oncologically ade-
quate—treatment. In 2004, Habr-Gama et al. [56] published
the long-term results of a retrospective study in which
71 patients (14 T2 and 49 T3) with clinical complete re-
sponse after long-course chemoradiation therapy (observa-
tion group) were compared with 22 patients who had
undergone surgery for incomplete clinical response and
had a final diagnosis of pT1 N0 M0 (resection group).
Among the observation group, after a mean follow-up
of 57.3 months, luminal recurrence occurred in 2.8% of
patients, while distant metastasis developed in 4.2%. No
pelvic recurrences were reported. Five-year overall and
disease-free survival rates were 100% and 92%, respec-
tively. In the resection group, three patients developed dis-
tant metastasis, while no luminal or pelvic recurrences
occurred. Five-year overall and disease-free survival rates
were 88% and 83%, respectively. Based on these results,
a ‘watch and wait’ strategy was proposed in patients with
clinical complete response. However, in a follow-up study
from the same group, that included 122 patients who were
initially considered to have a complete clinical response and
therefore managed conservatively [57], the authors re-
ported a local recurrence in 23 patients (18.9%), during the
first 12 months. After a mean follow-up of 59.9 months,
among the 99 patients included, luminal recurrence rate
was 5% and distant metastasis occurred in 7% of patients.
Overall and disease-free 5-year survivals were 93% and
85% respectively.
These data highlight the challenge of identifying
patients with a durable, complete clinical response. A cor-
relation, between tumor invasion of the rectal wall after
neoadjuvant chemoradiation and the risk of lymph node
metastasis has been observed, ranging from 2–17% in
ypT0-1 to 48% in ypT3-4 patients [58, 59]. More recent stud-
ies with longer intervals between completion of neoadju-
vant treatment and surgery have reported an incidence of
lymph node metastasis in ypT0 under 5% [60–63].
Reliable assessment of the rectal wall and nodal status
after chemoradiation remains challenging. Accuracy of the
available staging modalities is disappointing, due to the
radiation-induced fibrosis, edema and inflammation. In
addition, radiotherapy has been known to reduce both
the number and size of the perirectal lymph nodes [64].
In addition, the clinical correlation between complete
clinical response and pathological response is poor. Smith
et al. evaluated the clinical significance of residual mucosal
abnormalities after neoadjuvant therapy for rectal cancer
in 220 patients [65]. The diameter of residual mucosal
abnormalities correlated statistically with pathological
tumor stage, which was in turn associated with pathologi-
cal nodal status and lymph node ratio. Lymph node
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metastasis were retrieved in only one patient (4.2%) staged
as ypT0-1 and the risk of nodal metastasis was associated
with poor tumor differentiation and lympho-vascular inva-
sion. Interestingly, more than 50% of patients with a com-
plete pathological response did not have a complete clinical
response: residual mucosal abnormalities less than 3 cm
were strongly associated with ypT0-1 and a low rate (2%)
of lymph node metastasis. The authors concluded that
this subgroup of patients could be offered local excision
as a macrobiopsy, to rule out the persistence of cancer
within the rectal wall and to avoid the risks of an unneces-
sary TME.
The role of local excision after neoadjuvant chemoradia-
tion has been evaluated by several retrospective series and
reviewed in a pooled analysis by Borschitz et al. who
included 273 patients from seven different series [66].
They showed that the risk of local recurrence was strictly
correlated with the pathological staging observed after
chemoradiation. The strongest prognostic factors were
ypT0 (0% of local recurrence) and ypT1 (2%), while ypT2
was associated with increasing local recurrence rates of
6–20%, with a mean rate of 7%. This wide range of local
recurrences among ypT2 patients has to be interpreted
with caution, as ‘low risk’ ypT2 (G1-2, without lympho-
vascular invasion) may have a different clinical behavior,
compared with ‘high risk’ ypT2 (G3 and/or lympho-vascular
invasion). Not surprisingly, patients with no pathological
response (ypT3) showed a risk of local recurrence up
to 42%.
Nowadays, TEM is proposed as an integral component
of the multi-modality treatment of high selected T2 N0
rectal cancers. TEM equipment allows for stable exposure
of the surgical field, adequate assessment of the margin
and minimal risk of piecemeal excision, tumor fragmenta-
tion and seeding.
Lezoche et al. randomly assigned to TEM—or to rectal
resection combined with TME—70 patients with a pre-
operatively staged T2N0M0 G1-2 rectal cancer with a diam-
eter less than 3 cm after neoadjuvant combined modality
therapy [67]. A 30% rate of complete pathological response
was reported (32% in the TEM group and 29% in the lap-
aroscopic group). No differences were observed in terms
of local recurrences and survival between the two groups
at a median follow-up of 84 months. Notably, all recur-
rences occurred in patients without significant response
to neoadjuvant chemoradiation.
Recently, Garcia-Aguilar et al. reported the preliminary
results of the American College of Surgeons Oncology
Group (ACOSOG) Z6041 trial [68], looking at short-term
outcomes of neoadjuvant chemoradiation followed by
local excision—performed by conventional transanal tech-
nique or TEM—for treatment of 77 patients with a clinically
staged T2 N0 rectal cancer [68]. A complete pathological
response was achieved in 34 patients (44%), while
down-staging was observed in 49 patients (64%).
We recently reviewed the oncological outcomes of
43 patients who had undergone TEM for a T2 N0 rectal
cancer. Among these patients, 11 underwent pre-operative
radiotherapy. A response to radiation therapy in terms
of downsizing was observed in nine patients (82%), who
were then were treated by TEM while, in 2 two cases (18%),
a local tumor progression was observed. During a median
follow-up of 70 months (range: 36–140), all nine patients
with a downsized rectal cancer were alive and disease-free,
while both patients who had progression of the disease
died of distant metastasis [69].
While evidence supporting the role of TEM in a multi-
disciplinary strategy for the treatment of rectal cancer is
slowly increasing, concerns have recently been raised re-
garding the healing process in patients undergoing TEM
after neoadjuvant chemoradiation. Complication rates re-
lated to the rectal wound range from 0–60.9% [69, 70].
Marks et al. compared short-term outcomes of 43 rectal
cancer patients, treated by neoadjuvant chemoradiation
therapy followed by TEM (XRT group), with those of
19 patients treated by TEM alone [71]. The overall morbid-
ity rate was significantly higher in the XRT group (33 vs
5.3%; P< 0.05). In particular, the wound complication rate
was 25.6% for the XRT group (11 cases) and 0% for the
non-XRT group (P=0.015). However, ten patients (91%)
were treated conservatively and only one patient required
a diverting colostomy.
Perez et al. reported the 30-day results of 36 consecutive
patients treated by TEM for rectal neoplasm [70]: 23 under-
went chemoradiation therapy followed by TEM and 13
were managed by TEM alone for adenomas (four cases),
early adenocarcinomas (six patients), carcinoids (two
cases) and gastrointestinal stromal tumor (one patient).
They reported a significantly higher rate of suture line de-
hiscence (60.9 vs 23.1%; P= 0.032) and hospital readmission
(43.5 vs 7%; P= 0.025) among patients who had undergone
TEM after neoadjuvant chemoradiation. However, no
patient in this series required operative treatment to
repair the dehiscence. In addition, no differences were ob-
served in terms of late complications: one patient in each
group developed a symptomatic rectal stenosis that re-
quired rectal dilation.
Based on the data currently available, even though
neoadjuvant treatment seems to increase the rate of
wound-related complications after TEM, larger studies
with long follow-up periods are needed to evaluate the
risk of late complications and understand the implications
in terms of oncological outcomes. A European multicenter,
prospective study, Transanal Endoscopic Microsurgery
After Radiochemotherapy for Rectal Cancer (CARTS) has
been designed to investigate the role of TEM performed
8–10 weeks after pre-operative treatment on the basis of
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clinical response [72]. The short-term and the oncological
results of this study, along with those of ACOSOG Z6041,
may allow us to draw more definitive conclusions regarding
the role of transanal excision in the treatment of locally
advanced rectal cancer. Therefore, we feel that, at present,
TEM should be proposed for the treatment of T2 N0 rectal
cancer only in the context of study protocols after approval
by the local ethical committee.
Overall, there is increasing evidence that TEM may play a
major role in the multidisciplinary management of highly
selected T2 N0 rectal cancer patients with a significant
response to neoadjuvant therapy or a complete pathological
response. Transanal excision—and full-thickness TEM speci-
fically—should be considered a ‘staging’ biopsy, to allow for
a pathological evaluation of the specimen. Further decisions
regarding the surgical management (‘watch and wait’ vs
TME) should be made on the basis of the pathological eval-
uation, imaging study and tumor characteristics.
TEM and NOTES
In the NOTES (Natural Orifice Transluminal Endoscopic
Surgery) era, transrectal access to the peritoneal cavity
has been variously described [73–75]. Main concerns are
the safety of the access and the closure of the transvisceral
enterotomy. TEM has been proposed as a platform for
NOTES, since it is a well-established technique that allows
both full-thickness resection and suture of the rectal wall
defect. The feasibility of some transrectal NOTES proce-
dures (diagnostic peritoneoscopy, liver biopsy, sigmoid
resection) using TEM instrumentation, suggesting TEM as
a portal for NOTES, has been recently demonstrated in
experimental studies [76].
Even though satisfactory results have been achieved in
experimental (animal and human cadaver) models, the
potential clinical consequences of a transrectal NOTES pro-
cedure in humans, in terms of intra-abdominal contamina-
tion, leak of the enterotomy and risk of a stoma, are poorly
evaluated.
To our knowledge, only one case of NOTES transanal
rectal cancer using TEM and laparoscopic assistance has
been published [77]. Transanal endoscopic rectal resection
with TME using the TEM platform was performed in a
76-year-old woman after neoadjuvant chemoradiotherapy
for a T2N2 mid-rectal cancer. No postoperative complica-
tions occurred. The final pathological evaluation demon-
strated a complete TME with negative resections margins.
However, no long-term results in terms of recurrence and
survival are available.
In order to better clarify the effects of a peritoneal per-
foration (PP) during TEM on short-term and oncological
outcomes, we have recently reviewed our series of PP
during TEM for rectal neoplasm and compared the clinical
outcomes with the data available in the literature [78]. In
our experience of 481 patients, PP occurred in 28 cases
(5.8%). The indications for TEM were 23 adenomas and
5 carcinomas. PP was sutured by TEM in 25 cases (89.3%),
while conversion to abdominal surgery was necessary in
3 cases (10.7%). Notably, all conversions occurred during
the first 100 TEM procedures. By multivariate analysis, the
tumor distance 7 cm from the anal verge (P= 0.010) was
the only independent predictor for PP. The operative time
was significantly longer in case of intra-operative PP than
in uneventful TEM, while postoperative morbidity rate
(3.6 vs 6.2%) and type of complications were similar in
both groups. No mortality occurred in the series.
Globally, 17 studies have reported the number of PP
occurrences during TEM, with a mean PP rate of 4.8%
and a range from 0–32.3%, reflecting the fact that a sub-
mucosal dissection may be preferred over a full-thickness
excision in cases at risk for PP by some surgeons [78]. The
learning curve and the case volume of the surgeon are
two main factors that influence the treatment strategy to
be adopted when PP occurs. Notably, conversion to open
surgery was reported in 50–100% cases of PP only in series
with less than 100 patients, whereas it ranged from 0–40%
in larger series.
These data confirm the results obtained by Salm et al.
in a survey of 1900 TEM procedures [79]. They reported
that the conversion rate to laparotomy during TEM for all
causes, including inadvertent transrectal opening of the
peritoneal cavity, decreased with experience from 11.6%
(1–10 TEM procedures) to 1.2% (>100 TEM procedures).
In the short-term period, no cases of pelvic sepsis or
infectious complications after PP have been reported,
suggesting the fact that TEM seems not to be associated
with a higher risk of pelvic infection or other complications
when a PP occurs. Furthermore, the low morbidity rate and
the absence of pelvic infection complications demonstrate
that a defunctioning stoma is not generally necessary in
high-volume institutions.
Insufflation of CO2 from the rectum into the perito-
neum is considered a potential cause of oncological com-
plications in patients with colorectal cancer. At present,
very few data are available about oncological outcomes
after PP during TEM. To our knowledge, the only study
to evaluate the oncological results of patients undergoing
TEM with an inadvertent PP was that by Baatrup et al.
[80], who reported 22 perforations into the peritoneal
cavity during a total of 888 TEM procedures for rectal
cancer, performed at four European centers. During a
median follow-up of 36 months (range: 3–164), local recur-
rence developed in one pT1 patient (7%) and in one pT2
patient (25%), while distant metastasis were detected in
three patients.
In our series, over a median follow-up period longer
than 4 years, all patients in whom a PP occurred during
TEM for adenoma or pT1 rectal cancer are disease-free,
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with no sign of intraperitoneal seeding of adenomatous or
cancer tissue.
CONCLUSIONS
In 2013, TEM is the safest and most effective treatment
modality available for large rectal adenomas, with signifi-
cantly higher complete resection rates and lower local
recurrence rates than conventional transanal excision.
Further studies are needed to evaluated the safety and ef-
ficacy of TEM compared with EMR/ESD.
Non-ulcerated rectal cancers, with the tumor invasion
confined to the superficial submucosa (i.e. pT1 sm1), well
or moderately differentiated, without lymphovascular inva-
sion, are the only malignant lesions currently suitable
for TEM. In this highly select group of cancers, TEM alone
provides oncological outcomes that approximate to those
of abdominal surgery.
For pT1 sm2–3 and pT2 cancers, TEM as sole treatment
modality is not recommended because of the high risk
of lymph node metastasis. Future studies are needed to
investigate the role of TEM in association with neoadjuvant
therapy in this subgroup of patients. Furthermore, we
are at present investigating the technical possibility of
performing sentinel lymph node sampling in oncological
TEM procedures.
In the NOTES era, we feel that the application of the
transanal approach to NOTES should be limited only to
selected academic centers with extensive expertise in
TEM. Large studies with long follow-up periods are
requested before this approach can be widely applied to
the treatment of colorectal cancer.
Conflict of interest: none declared.
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